M
Monica Bellei
Researcher at University of Modena and Reggio Emilia
Publications - 68
Citations - 5009
Monica Bellei is an academic researcher from University of Modena and Reggio Emilia. The author has contributed to research in topics: Follicular lymphoma & ABVD. The author has an hindex of 25, co-authored 66 publications receiving 4364 citations. Previous affiliations of Monica Bellei include University of Wisconsin-Madison.
Papers
More filters
Journal ArticleDOI
Clinicopathologic Characteristics of Angioimmunoblastic T-Cell Lymphoma: Analysis of the International Peripheral T-Cell Lymphoma Project
Massimo Federico,Thomas Rüdiger,Monica Bellei,Bharat N. Nathwani,Stefano Luminari,Bertrand Coiffier,Nancy L. Harris,Elaine S. Jaffe,Stefano Pileri,Kerry J. Savage,Dennis D. Weisenburger,James O. Armitage,Nicholas Mounier,Julie M. Vose +13 more
TL;DR: AITL is a rare clinicopathologic entity characterized by an aggressive course and dismal outcome with current therapies, and the alternative Prognostic Index for AITL (PIAI), a low-risk group (zero to one factors), with 5-year survival of 44%, is evaluated.
Journal ArticleDOI
Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial
Anne-Ségolène Cottereau,Annibale Versari,Annika Loft,Olivier Casasnovas,Monica Bellei,Romain Ricci,Stéphane Bardet,Antonio Castagnoli,Pauline Brice,John M. M. Raemaekers,Bénédicte Deau,Catherine Fortpied,Tiana Raveloarivahy,Emelie van Zele,Loïc Chartier,Thierry Vander Borght,Massimo Federico,Martin Hutchings,Umberto Ricardi,Marc André,Michel Meignan +20 more
TL;DR: B baseline positron emission tomography/computed tomography improves baseline risk stratification of patients with early-stage HL compared with current staging systems and the predictive value of early PET response as well.
Journal ArticleDOI
High-Dose Therapy and Autologous Stem-Cell Transplantation Versus Conventional Therapy for Patients With Advanced Hodgkin’s Lymphoma Responding to Front-Line Therapy
Angelo Michele Carella,Monica Bellei,Pauline Brice,Christian Gisselbrecht,Giuseppe Visani,Philippe Colombat,Francesco Fabbiano,Amedea Donelli,Stefano Luminari,Pierre Feugier,Peter Browett,Hans Hagberg,Massimo Federico +12 more
TL;DR: Patients with advanced unfavorable HL achieving CR or PR after four courses of doxorubicin-containing regimens have a favorable outcome with conventional chemotherapy, and no benefit from an early intensification with HDT and ASCT was shown.
Journal ArticleDOI
Molecular Profiling Improves Classification and Prognostication of Nodal Peripheral T-Cell Lymphomas: Results of a Phase III Diagnostic Accuracy Study
Pier Paolo Piccaluga,Fabio Fuligni,Antonio De Leo,Clara Bertuzzi,Maura Rossi,Francesco Bacci,Elena Sabattini,Claudio Agostinelli,Anna Gazzola,Maria Antonella Laginestra,Claudia Mannu,Maria Rosaria Sapienza,Sylvia Hartmann,Martin L. Hansmann,Roberto Piva,Javeed Iqbal,John C. Chan,D. D. Weisenburger,Julie M. Vose,Monica Bellei,Massimo Federico,Giorgio Inghirami,Pier Luigi Zinzani,Stefano Pileri +23 more
TL;DR: A phase III diagnostic accuracy study to test the ability of gene expression profiles (GEPs; index test) to identify PTCL subtype supports the usage of an MC as additional tool in the diagnostic workup of nodal P TCL.
Journal ArticleDOI
Watchful Waiting in Low–Tumor Burden Follicular Lymphoma in the Rituximab Era: Results of an F2-Study Database
Philippe Solal-Celigny,Monica Bellei,Luigi Marcheselli,Emanuela Anna Pesce,Stefano Pileri,Peter McLaughlin,Stefano Luminari,Barbara Pro,Silvia Montoto,Andrés J.M. Ferreri,Eric Deconinck,Noel Milpied,Leo I. Gordon,Massimo Federico +13 more
TL;DR: In the rituximab era, patients with follicular lymphoma in a selected prognostically favorable group can still be managed with W&W and does not seem to have detrimental effects on FFTF and overall survival rates after treatment.